Alzheimer’s Disease (AD) is a worldwide problem that does not yet have a clear solution. Although new treatments are starting to emerge, they do not work for every patient. The reason is likely individual difference in the specific, molecular, causes of AD. In our project, we will explore an innovative method to classify AD patients and guide personalized treatment selection and treatment development. We hope this custom approach allows successfully treating more AD cases.
With his project tRNA for CMT, Erik and his team are currently part of the Biotech Booster program and are
Biotech Booster connects Business Developers and the newly introduced Impact Developers to the broader ecosystem. While both roles focus on
The Biotech Booster team spoke with Allison Wolder, co-founder of Tulip Enzyme Solutions, a Biotech Booster project that joined the
“Humans create a lot of waste. We are the only species in the world that create so much persistent waste
Biotech Booster connects Business Developers and the newly introduced Impact Developers to the broader ecosystem. While both roles focus on
Biotech Booster connects Business Developers and the newly introduced Impact Developers to the broader ecosystem. While both roles focus on
Biotech Booster helps us through funding and by providing us with a network to validate where we can make the best impact with our new analysis device.
Constellate
What we look forward to most is leveraging the extraordinary network of Biotech Booster that we need to get foot in the market, get know-how, and understanding the competitive field which is necessary for setting up successful operations.
ProteoT
Receive monthly updates about our community!
